Profile data is unavailable for this security.
About the company
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
- Revenue in USD (TTM)25.00k
- Net income in USD-44.19m
- Incorporated2018
- Employees2.00
- LocationImpact Biomedical Inc1400 Broadfield Blvd., Suite 130HOUSTON 77084United StatesUSA
- Phone+1 (585) 232-1500
- Websitehttps://www.impactbiomedinc.com/
More ▼
Mergers & acquisitions
| Acquired company | IBO:ASQ since announced | Transaction value |
|---|---|---|
| Celios Corp | -74.59% | 1.15m |
Data delayed at least 15 minutes, as of Feb 11 2026 19:54 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABVC Biopharma Inc | 797.92k | -4.12m | 43.86m | 16.00 | -- | 3.41 | -- | 54.97 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 44.18m | 70.00 | -- | 0.6151 | -- | 16.70 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| OS Therapies Inc | 0.00 | -20.26m | 44.37m | 4.00 | -- | 11.53 | -- | -- | -0.9794 | -0.9794 | 0.00 | 0.1415 | 0.00 | -- | -- | 0.00 | -334.55 | -- | -870.52 | -- | -- | -- | -- | -- | -- | -2,674.49 | 0.00 | -- | -- | -- | -37.51 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -61.71m | 45.55m | 55.00 | -- | 0.549 | -- | -- | -8.44 | -8.44 | 0.00 | 11.33 | 0.00 | -- | -- | 0.00 | -47.14 | -34.75 | -54.13 | -36.82 | -- | -- | -- | -5,003.10 | -- | -- | 0.0742 | -- | -100.00 | -- | 17.80 | -- | -45.57 | -- |
| UMeWorld Inc | 7.93k | -1.32m | 47.06m | 1.00 | -- | -- | -- | 5,934.66 | -0.0148 | -0.0148 | 0.00009 | -0.0477 | 0.1253 | -- | 1.71 | 7,930.00 | -2,066.65 | -273.32 | -- | -- | -285.62 | -768.98 | -16,497.98 | -13,102.00 | -- | -2.36 | -- | -- | 136.17 | -- | -15.02 | -- | -- | -- |
| CervoMed Inc | 6.16m | -25.58m | 47.19m | 15.00 | -- | 1.81 | -- | 7.66 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Q32 Bio Inc | 0.00 | -42.10m | 47.49m | 26.00 | -- | -- | -- | -- | -3.45 | -3.45 | 0.00 | -1.50 | 0.00 | -- | -- | 0.00 | -51.87 | -36.08 | -61.53 | -39.62 | -- | -- | -- | -870.34 | -- | -- | -- | -- | -100.00 | -- | 57.74 | -- | -67.85 | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 47.77m | 2.00 | -- | -- | -- | 1,910.80 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Clene Inc | 214.00k | -30.50m | 47.96m | 75.00 | -- | -- | -- | 224.10 | -3.33 | -3.33 | 0.0231 | -1.21 | 0.0079 | 0.4021 | 0.475 | 2,853.33 | -113.20 | -55.54 | -280.47 | -72.66 | 82.24 | 76.19 | -14,250.47 | -6,165.10 | 1.52 | -8.71 | 3.64 | -- | -47.71 | -- | 20.41 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 48.49m | 21.00 | -- | 6.85 | -- | 9.22 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Lipocine Inc | 4.32m | -5.48m | 48.91m | 16.00 | -- | 3.38 | -- | 11.32 | -1.04 | -1.04 | 0.7933 | 2.61 | 0.2351 | -- | 41.82 | 270,168.10 | -29.78 | -30.54 | -32.92 | -34.86 | -- | -- | -126.66 | -194.90 | -- | -- | 0.00 | -- | 492.80 | 132.45 | 100.05 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 49.23m | 75.00 | -- | 0.3827 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 50.43m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 50.67m | -- | -- | 6.33 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Impact Biomedical Inc's reporting currency: US Dollar USD
1.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 512.69k | 0.49% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 269.99k | 0.26% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 252.73k | 0.24% |
| Geode Capital Management LLCas of 30 Sep 2025 | 45.11k | 0.04% |
| Vanguard Global Advisers LLCas of 31 Dec 2025 | 32.20k | 0.03% |
| Two Sigma Investments LPas of 30 Sep 2025 | 31.50k | 0.03% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 28.44k | 0.03% |
| G1 Execution Services LLCas of 30 Sep 2025 | 20.96k | 0.02% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 11.80k | 0.01% |
| Mason & Associates, Inc.as of 31 Dec 2025 | 10.00k | 0.01% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
